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one morphogenetic proteins (BMPs) regulate multiple
cellular processes, including cell differentiation and
migration. Their signals are transduced by the kinase
receptors BMPR-I and BMPR-II, leading to Smad transcription
factor activation via BMPR-I. LIM kinase (LIMK) 1 is a key
regulator of actin dynamics as it phosphorylates and in-
activates coﬁlin, an actin depolymerizing factor. During a
search for LIMK1-interacting proteins, we isolated clones
encompassing the tail region of BMPR-II. Although the
BMPR-II tail is not involved in BMP signaling via Smad
B
 
proteins, mutations truncating this domain are present in
patients with primary pulmonary hypertension (PPH). Further
analysis revealed that the interaction between LIMK1 and
BMPR-II inhibited LIMK1’s ability to phosphorylate coﬁlin,
which could then be alleviated by addition of BMP4. A
BMPR-II mutant containing the smallest COOH-terminal
truncation described in PPH failed to bind or inhibit
LIMK1. This study identiﬁes the ﬁrst function of the
BMPR-II tail domain and suggests that the deregulation of
actin dynamics may contribute to the etiology of PPH.
 
Introduction
 
LIM kinase 1 (LIMK1) regulates actin dynamics by phos-
phorylating cofilin on serine 3, rendering it inactive, as
phosphorylated cofilin is unable to bind actin and mediate
actin depolymerization (Arber et al., 1998; Yang et al.,
1998). In turn, LIMK1 is activated after phosphorylation
by two protein kinases, p21-activated kinases (PAKs) and
Rho-associated kinase (ROCK) (Edwards et al., 1999;
Maekawa et al., 1999; Dan et al., 2001), effectors of the
small GTPases Rac, Cdc42, and Rho. In addition to its ki-
nase domain, LIMK1 contains two LIM domains and one
PDZ domain. These domains mediate protein–protein
interactions and are suggested to regulate the activity of
LIMK1, as deletion mutants lacking these domains show
increased  LIMK1 activity (Arber et al., 1998). Previous
yeast two-hybrid and mammalian cell interaction analyses
have revealed that LIMK1 interacts via its LIM domains
with at least two other non-LIM proteins, PKC (Kuroda et
al., 1996) and the cytoplasmic domain of the transmembrane
ligand neuregulin (Wang et al., 1998). However, no function
was assigned to these interactions. Recently, it was identified
that both LIMK1 and cofilin interact with the scaffolding
protein 14-3-3 
 
 
 
 (Gohla and Bokoch, 2002; Birkenfeld et
al., 2003). The 14–3-3 
 
 
 
 protein also binds to phospho-
cofilin and may cooperate with LIMK1 in maintaining
phospho-cofilin levels (Gohla and Bokoch, 2002).
Bone morphogenetic protein receptors (BMPRs) are
transmembrane serine/threonine protein kinases that belong
to the TGF
 
 
 
 family of receptors and consist of type I and
type II proteins. Ligand binding leads the type II BMPR
(BMPR-II) to phosphorylate and activate the type I receptors,
BMPR-IA (also known as ALK3) and BMPR-IB (ALK6).
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BMPR-I, in turn, phosphorylates Smad proteins, causing
their activation and translocation to the nucleus where they
regulate the transcription of BMP-responsive genes (Shi and
Massague, 2003).
The only function of the TGF
 
 
 
 family type II receptors
known to date is the phosphorylation of type I receptors. Un-
like other TGF
 
 
 
 type II receptors, however, BMPR-II has a
large cytoplasmic tail of 
 
 
 
600 amino acids COOH terminal
to the kinase domain. This domain is present in the most
abundant splice form of BMPR-II, and a similar domain (al-
beit of very different amino acid sequence) is also present in
the 
 
Drosophila
 
 BMPR-II (Aberle et al., 2002; Allan et al.,
2003). To date, no function has been assigned to this do-
main, as it is not required for BMP signaling through the
Smad pathway (Wieser et al., 1993; Nishihara et al., 2002).
Mutations within BMPR-II are implicated in the rare au-
tosomal dominant disorder primary pulmonary hyperten-
sion (PPH), which is characterized by the proliferation of
pulmonary artery smooth muscle and endothelial cells, re-
sulting in occlusion of pulmonary vessels and increased
blood pressure followed by heart failure (Morrell et al.,
2001). Many of the 
 
BMPRII
 
 mutations identified in PPH
occur downstream of the kinase domain and are either
frameshift or nonsense mutations that are predicted to trun-
cate the tail domain (Lane et al., 2000; Thomson et al.,
2000; Machado et al., 2001). These observations suggest
that the tail may play an important role in the regulation of
pulmonary artery wall homeostasis.
Here, we demonstrate that LIMK1 interacts specifically
with the tail of BMPR-II via its LIM domains and that this
interaction results in the down-regulation of LIMK1 activ-
ity. We show that BMP4 ligand stimulation alleviates this
down-regulation, resulting in increased levels of phospho-
cofilin and changes to the actin cytoskeleton and subcellular
localization of LIMK1. Furthermore, a mutation in the
BMPR-II mimicking the most COOH-terminal mutation
in PPH reduces the ability of BMPR-II to bind and inhibit
LIMK1, raising the possibility that LIMK1 is involved in
the etiology of PPH.
 
Results
 
LIMK1 interacts with the tail of BMPR-II
 
To identify new molecules that regulate LIMK1 activity, we
conducted yeast two-hybrid screens (Fields and Song, 1989)
to isolate LIMK1-associated proteins (LAPs). After screen-
ing of mouse embryonic and human brain cDNA libraries
using full-length LIMK1 fused to the GAL4 DNA binding
domain as bait, two clones from each library interacted
strongly with LIMK1 but did not interact with two negative
control baits (Jun and Lck) or empty vector. These four
clones were picked for further analysis as they demonstrated
the greatest 
 
 
 
-galactosidase activity and hence the strength
of interaction in this particular assay system. Sequence anal-
ysis of these LAPs (mLAP16, mLAP22, hLAP15, and
hLAP41) revealed that they all contained cDNA inserts
corresponding to a region within the cytoplasmic tail of
BMPR-II (Fig. 1 A). The interaction between LIMK1 and
the tail of BMPR-II was confirmed in mammalian cells. The
cDNAs of the three LAPs (mLAP16, hLAP15, and hLAP41)
Figure 1. Immunoprecipitation analyses of overexpressed 
LIMK1 and its interaction with BMPR-II proteins in COS-7 cells. 
(A) Schematic representation of full-length and truncated BMPR-II 
proteins. The extracellular domain (gray), the transmembrane and 
kinase domains (small and large black areas, respectively), and the 
cytoplasmic tail (white) are presented. The numbers of the amino 
acid residues are indicated above each structure as well as the site 
of the most COOH-terminal mutation currently identified in PPH 
patients, R873X. (B) Immunoprecipitation and immunoblot analyses 
of GFP-tagged LAPs interacting with FLAG-tagged LIMK1 (F-LIMK1) 
but not FLAG–Btk (F-Btk). (C) GST-tagged LIMK1 interaction with 
full-length myc-tagged BMPR-II (M-BMPR-II) or FLAG-tagged 
truncated BMPR-II (F-BMPR-II-T; contains no cytoplasmic tail).T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
BMPR-II inhibits the activity of LIMK1 |
 
 Foletta et al. 1091
 
were subcloned into GFP-encoding expression vectors and
were coexpressed with either FLAG-tagged LIMK1 or Btk, a
cytoplasmic protein kinase unrelated in function to LIMK1,
in COS-7 cells. The FLAG-tagged proteins were immu-
nopurified with FLAG M2 beads, and interacting proteins
were detected by Western blotting with an anti-GFP anti-
body (Fig. 1 B). All three LAPs interacted with LIMK1
(lanes 7–9) but not with Btk (lanes 4–6) or with the FLAG
beads alone (lanes 1–3).
To determine whether full-length BMPR-II, which nor-
mally localizes to the cell membrane as part of a BMPR com-
plex, associates with LIMK1, full-length myc-tagged BMPR-
II was coexpressed with either GST or GST–LIMK1 in
COS-7 cells. Cell lysates were incubated with glutathione-
Sepharose beads, and the bound proteins were analyzed by
immunoblotting with an anti–BMPR-II antibody (Fig. 1 C).
Full-length BMPR-II was observed to bind to GST–LIMK1
(lane 1) but not to GST (lane 3), suggesting that BMPR-II
interacts with LIMK1 in mammalian cells. We also found
that the other member of the LIMK family, LIMK2, inter-
acted with full-length BMPR-II when both proteins were
overexpressed in COS-7 cells (unpublished data).
Studies by Liu et al. (1995) suggested that BMPR-II ex-
isted as two isoforms generated by alternative splicing. These
isoforms differed in that one, BMPR-IIs, lacked the long cy-
toplasmic region identified as LIMK1-interacting domain in
our yeast two-hybrid screen. To investigate whether the re-
gion required for the interaction between BMPR-II and
LIMK1 occurs specifically within the cytoplasmic tail region
of BMPR-II, we performed pull-down experiments using a
truncated version of BMPR-II, which does not possess the
cytoplasmic tail (amino acid residues 1–559; Fig. 1 A).
Truncated BMPR-II was unable to bind GST–LIMK1 or
GST alone (Fig. 1 C, lanes 2 and 4). These results suggested
that only the long form of BMPR-II was able to interact
with LIMK1.
 
In vivo interaction between endogenous LIMK1
and BMPR-II
 
It is possible that the interaction between overexpressed
BMPR-II and GST–LIMK1 was driven by the large
amounts of the proteins produced in the COS cell overex-
pression system. To address this issue, we sought to deter-
mine if the interaction occurred between endogenously
expressed proteins in tissue culture cells. Initially, we per-
formed a survey of human and mouse cell lines for expres-
sion of LIMK1, BMPR-II, and the alternative spliced pro-
tein lacking the cytoplasmic tail, BMPR-IIs (Liu et al.,
1995). RNAs encoding the BMPR-IIs were of particular
interest because our results implied that cells might be able
to modulate the amount of BMPR-II–LIMK1 complex by
altering the proportion of BMPR-II to BMPR-IIs. How-
ever, Northern blot analysis of most of the cell lines exam-
ined, which included human HaCaT keratinocytes, HPL1
lung epithelial cells, HUVEC umbilical cord endothe-
lial  cells, WI38 lung fibroblasts, A549 lung carcinoma,
HepG2 hepatoma, and mouse NMuMG mammary epithe-
lial cells, C2C12 myoblasts, and NIH3T3 mouse embryo
fibroblasts, showed mRNA expression of 
 
BMPRII
 
 and
 
Limk1
 
 but not 
 
BMPRIIs
 
 (unpublished data). To facilitate
the analysis of BMPR-II–LIMK1 interactions, we raised
rabbit polyclonal antibodies against the kinase domain and
the cytoplasmic tail of BMPR-II domain (Fig. 2 A) in ad-
dition to using a mouse monoclonal anti-LIMK1 antibody
that recognizes endogenous LIMK1 protein. Western im-
munoblotting of cell lysates using these antibodies after a
survey of selected cell lines revealed that BMPR-II is ex-
pressed in all cell lines tested (Fig. 2 B; unpublished data).
Figure 2. Interaction between endogenous LIMK1 and BMPR-II. 
(A) Schematic representation of BMPR-II, the short alternatively 
spliced isoform BMPR-IIs and the COOH-terminal tail construct, 
and recognition of these proteins, expressed in COS-7 cells as 
HA-tagged constructs, by anti–kinase domain and anti-tail 
domain antibodies. M, transmembrane region. (B) Recognition of 
endogenous BMPR-II by anti–BMPR-II-tail antibodies in Western 
immunoblotting of lysates from the indicated cell lines. (C) Association 
of endogenous BMPR-II and LIMK1 in NIH3T3 cells. Lysates from 
NIH3T3 cells were immunoprecipitated with anti–BMPR-II-tail 
antibodies, and the presence of BMPR-II and LIMK1 in the immuno-
complexes was determined by Western immunoblotting with the 
indicated antibodies. Two percent of the total lysate used for 
immunoprecipitation was tested by immunoblotting for LIMK1 
expression (Lysate). FLAG-tagged LIMK1 and HA-tagged BMPR-II 
immunoprecipitated from transfected COS-7 cells with antibodies 
against these epitopes served as marker controls.T
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NIH3T3 fibroblasts, which express an intermediate level
of BMPR-II, also expressed a moderate level of LIMK1
(Fig. 2 C) and were used to investigate the interaction be-
tween these two endogenous proteins. Immunoprecipita-
tion of cell lysates with anti–BMPR-II (tail) antibodies fol-
lowed by Western immunoblotting of these precipitates
with mouse anti-LIMK1 monoclonal antibody demon-
strated an interaction between endogenous BMPR-II and
LIMK1 proteins (Fig. 2 C).
 
BMPR-II mapping of the LIMK1 binding region
 
Having established that the tail of BMPR-II was required for
its interaction with LIMK1, we then sought to define the
minimal region within the tail required for this interaction.
The sequences responsible for the LIMK1–BMPR-II inter-
action were further defined by creating myc-tagged BMPR-
II tail deletion constructs. Plasmids encoding truncated ver-
sions of hLAP15 (hLAP15s, amino acids 742–932) and
mLAP16 (mLAP16s, amino acids 742–1038) (Fig. 1 A)
were cotransfected with constructs encoding either GST–
LIMK1 or GST alone. After affinity purification with glu-
tathione-Sepharose beads, proteins that copurified with the
GST fusion proteins were detected using an anti-myc anti-
body (Fig. 3 A). Both mLAP16s and mLAP15s interacted
with GST–LIMK1 but not with GST, indicating that the
minimal region required for BMPR-II interaction with
LIMK1 is contained within a 190–amino acid region lo-
cated COOH terminal to the BMPR-II kinase domain.
Figure 3. Analysis of LIMK1 and BMPR-II interaction. (A) GST–LIMK1 interaction with myc-tagged LAP proteins (M-hLAP15s and 
M-mLAP16s); isolated regions of the cytoplasmic tail of BMPR-II. (B) GST–LIMK1 interaction with wild-type, untagged BMPR-II and mutated 
BMPR-II (B-R873X) containing a COOH-terminal mutation (see Fig. 1 A). (C) FLAG-tagged LIM and PDZ domains of LIMK1 (F-LIM1,2 and 
F-PDZ) and full-length F-LIMK1, but not FLAG-tagged LIMK1 kinase domain (F-KIN) or F-Btk, interact with full-length BMPR-II. A schematic 
diagram of the LIMK1 domains is represented below the panels. The LIM domains (dark gray), PDZ domain (black), and kinase region (light 
gray) are indicated. (D) Association of two different amounts (10 and 20  l) of GST–LIMK1 bound to glutathione-Sepharose beads with 
HA–PAK4 (lanes 1 and 4), BMPR-II (lanes 2 and 5), and both PAK4 and BMPR-II (lanes 3 and 6). Numbers above the blots indicate the fold 
change in HA–PAK4’s ability to bind GST–LIMK1 in the presence and absence of overexpressed BMPR-II.T
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BMPR-II mutation that mimics the most COOH-
terminal mutation in PPH affects binding to LIMK1
 
The region of 190 amino acids in the tail of BMPR-II en-
compasses sequences that are affected by mutations associ-
ated with PPH (Machado et al., 2001). To test whether such
mutations influence the binding of BMPR-II to LIMK1, we
created a BMPR expression construct encoding a BMPR-II
bearing a mutation in amino acid 873 (R873X) that mimics
the most COOH-terminal mutation known in PPH (Ma-
chado et al., 2001) (Fig. 1 A). This PPH mutant was chosen
because it represents the smallest (minimal) deletion in the
tail region of BMPR-II.
In immunoprecipitation experiments, the amount of
BMPR-II (R873X) protein coimmunoprecipitated with
LIMK1 was only 15% of the wild-type BMPR-II after ad-
justment for the level of expression of each protein (Fig. 3
B). These results suggest that the interaction between
LIMK1 and all of the various mutated BMPR-II receptors
present in PPH is likely to be diminished or abolished.
 
The LIM domains of LIMK1 mediate the interaction 
with the tail of BMPR-II
 
To identify the region of LIMK1 mediating the interaction
with BMPR-II, FLAG-tagged domains of LIMK1 (Fig. 3 C)
were coexpressed with full-length BMPR-II in COS-7 cells.
Cell lysates were incubated with FLAG M2 beads, and the
bound proteins were analyzed by immunoblotting using an
anti–BMPR-II antibody. BMPR-II interacted strongly with
both full-length LIMK1 (Fig. 3 C, lane 9) and the LIM do-
mains (lane 3), interacted weakly with the PDZ domain
(lane 5), and did not interact with the kinase domain or the
negative control, Btk (lanes 7 and 11). These results indicate
that LIMK1 binds to BMPR-II primarily via its LIM do-
mains, possibly with some contribution from the PDZ do-
main. The specificity of association between BMPR-II and
the LIM domains of LIMK1 was further verified after coim-
munoprecipitation analysis with overexpressed BMPR-II
and the LIM domain protein LMO2 (Larson et al., 1996)
where no interaction was observed (unpublished data). Al-
though it is likely that the LIM domains of LIMK1 interact
directly with the tail of BMPR-II, it is possible that this in-
teraction is assisted by another protein such as a scaffolding
protein or even actin. Previous yeast-two hybrid and mam-
malian cell interaction analyses have revealed that LIMK1
also interacts via its LIM domains with at least two other
proteins, PKC (Kuroda et al., 1996) and the transmembrane
ligand neuregulin (Wang et al., 1998). However, neither
PKC nor neuregulin share any common sequence motifs
with the 190–amino acid region of BMPR-II that binds
LIMK1, and we were unable to identify any known protein
binding motifs or recognizable functional domains within
this 190–amino acid region.
 
BMPR-II competes with PAK4 for interaction 
with LIMK1
 
PAK and ROCK activate LIMK1 after interaction with its
LIM domains followed by phosphorylation of threonine
508. To examine whether BMPR-II could compete with
PAK for the interaction with LIMK1, we performed copuri-
fication assays with LIMK1 and PAK4 in the presence and
absence of overexpressed BMPR-II. GST–LIMK1, HA–
PAK4, and BMPR-II were expressed separately in COS-7
cells. GST–LIMK1 was purified on glutathione-Sepharose
beads, and 10 or 20 
 
 
 
l of the beads containing purified
LIMK1 was added to equal volumes of cell lysates of COS
cells expressing either HA–PAK4, BMPR-II, or both. After
washings, proteins that copurified with LIMK1 were de-
tected by immunoblotting using anti-HA and anti–BMPR-
II antibodies. As expected, both PAK4 and BMPR-II bind
strongly to LIMK1 alone; however, in the presence of
BMPR-II, the amount of PAK4 that copurified with
LIMK1 was reduced by 2.86- and 2.3-fold for 10 and 20 
 
 
 
l
of GST–LIMK1, respectively (Fig. 3 D).
 
BMPR-II is a negative regulator of LIMK1 activity
 
As endogenous LIMK1 and BMPR-II were found to associ-
ate, we examined if this interaction affected their known ac-
tivities. To assess this, the ability of LIMK1 to phosphory-
late cofilin using in vitro kinase assays in the presence or
absence of BMPR-II was examined. Myc-tagged LIMK1
and myc-tagged BMPR-II were expressed separately in COS
cells and then immunoprecipitated with anti-myc antibodies
either alone or together after the lysates were combined. The
immunocomplexes were labeled in vitro with [
 
32
 
P]
 
 
 
-ATP to
determine their level of activity. Both kinase molecules ex-
hibited high levels of autophosphorylation when assayed in-
dividually (Fig. 4 A). In addition, LIMK1, but not BMPR-II,
was able to phosphorylate 5 
 
 
 
g of recombinant GST–cofilin
present in all samples (Fig. 4 A). However, when LIMK1
and BMPR-II were coimmunopurified, a decrease in the
level of phosphorylated GST–cofilin was observed with no
change evident in the level of phosphorylation of LIMK1 or
BMPR-II. All samples were normalized for the amount of
LIMK1 protein present, as determined by densitometry
analysis of immunoblotted LIMK1. The level of GST–
cofilin phosphorylation by LIMK1 was reduced up to five-
fold after LIMK1 interaction with BMPR-II in six individ-
ual experiments performed where an average of 0.45 
 
 
 
 0.10
SEM was measured and compared with 1.0, the value given
to the level of phosphorylated GST–cofilin in the presence
of myc-tagged LIMK1 alone (Fig. 4 A). A reduction in
GST–cofilin phosphorylation was confirmed in experiments
where protein lysates containing FLAG-tagged or GFP-
tagged LIMK1 proteins were combined with myc-tagged
BMPR-II protein lysates and coimmunopurified using ei-
ther anti-FLAG or anti-GFP antibodies, respectively (Fig. 4
B), and tested for their ability to phosphorylate cofilin. After
normalization for LIMK1 protein, a reproducible decrease
in the phosphorylation of GST–cofilin was evident (Fig. 4
B), as shown in Fig. 4 A. In addition, the activity of the
LIMK1 kinase domain alone, as judged by its ability to
phosphorylate cofilin, was not affected by the presence of
BMPR-II (Fig. 4 B), indicating that the interaction between
the two molecules leads to down-regulation of LIMK1 activ-
ity. Moreover, the presence of a tailless BMPR-II receptor
did not affect the activity of LIMK1 (Fig. 4 C). The PPH-
like mutant BMPR-II (R873X) did not affect the ability of
LIMK1 to phosphorylate cofilin (unpublished data), sup-
porting the notion that PPH mutations may compromiseT
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the regulation of LIMK1. Finally, in a separate set of experi-
ments, the interaction of LIMK1 with BMPR-II did not ap-
pear to alter the ability of BMPR-II to phosphorylate
BMPR-IA (unpublished data).
 
BMP4 increases the activity of LIMK1
 
To demonstrate that the interaction between LIMK1 and
BMPR-II has biological significance, we studied the effect of
BMP4 on the activity of LIMK1. As the only known sub-
strate of LIMK1 is cofilin, change in the level of phospho-
cofilin is a surrogate measure of LIMK1 activity. COS-7
cells were serum starved and then incubated in the presence
or absence of 10 ng/ml BMP4 for periods of 5–30 min and
compared with unstimulated cells. Cell lysates were sub-
jected to immunoblotting with anti–phospho-cofilin anti-
bodies. Western blot filters were subsequently stripped and
reprobed with anti-cofilin antibodies to allow the absolute
amount of cofilin to be measured. Incubation with BMP4
for 5 min resulted in a sevenfold increase in the level of
phospho-cofilin compared with controls. An increased level
of phospho-cofilin was maintained, but to a lesser extent af-
ter 10 and 30 min incubation with BMP4, relative to that
found in untreated cells (Fig. 5 A).
We next examined the possibility that BMP4 also in-
creases the activity of overexpressed LIMK1 in the presence
of overexpressed BMPR-II. COS-7 cells were transfected
separately with GST–LIMK1 and both GST–LIMK1 and
BMPR-II. The cells were stimulated with 10 ng/ml BMP4
for 10 min, and lysates of stimulated and nonstimulated
cells were subjected to immunoblot analysis using anti-
phospho-cofilin and anti-cofilin antibodies. Expression of
LIMK1 resulted in a 3.9-fold increase in the level of phos-
pho-cofilin, in comparison with nontransfected cells (Fig. 5
B, lane 2). In the presence of BMP4, the level of phospho-
cofilin in the LIMK1-expressing cells was increased 5.2-fold
in comparison with nontransfected, nonstimulated cells
(Fig. 5 B, lane 3). The level of phospho-cofilin in BMP4-
stimulated LIMK1- and BMPR-II–transfected cells was sim-
ilar to that of LIMK1-transfected cells (Fig. 5 B, lane 5),
indicating that BMP4 stimulation can overcome the inhibi-
tion of LIMK1 activity caused by BMPR-II.
Given the effects that the interaction between LIMK1 and
BMPR-II has on LIMK1 activity, an obvious question that
arises is whether BMPs can induce discernible short-term ef-
fects on the cells’ cytoskeletal architecture. Therefore, we in-
vestigated the effects of BMP4 on the subcellular localiza-
tion of endogenous LIMK1 and the arrangement of F-actin.
Immunofluorescence analysis of unstimulated COS-7 cells
demonstrated that endogenous LIMK1 predominantly re-
sides in the cytosol with a perinuclear distribution. Lower
levels of LIMK1 were also present at the plasma membrane
at the leading edge of the cell where it colocalized with
 
(C) In vitro kinase assays of immunoprecipitated GFP–LIMK1 in the 
presence or absence of tailless kinase dead BMPR-II (BMPRII-T-KD). 
5 
 
 
 
g of GST–cofilin is used as substrate in all samples. Phosphory-
lated proteins (arrowheads, top panel) and their level of expression 
after immunoblotting (arrows, bottom panel) are indicated. The fold 
change in GST–cofilin phosphorylation by LIMK1 was calculated as 
described above.
Figure 4.
 
Inhibition of LIMK1 function after interaction with 
BMPR-II.
 
 (A) In vitro kinase assay of coimmunoprecipitated myc-
tagged LIMK1 and BMPR-II (M-LIMK1 and M-BMPR-II) proteins using 
5 
 
 
 
g of GST–cofilin as substrate. Autophosphorylated M-LIMK1 and 
M-BMPR-II and phosphorylated GST–cofilin (arrowheads) and their 
level of expression as determined by immunoblotting (arrows) are 
indicated at the top and bottom panels, respectively. The level of 
cofilin phosphorylation is an indication of LIMK1 activity, and the 
fold change in cofilin phosphorylation was calculated by Phosphor-
Image analysis after normalization for the level of LIMK1 expression as 
determined by immunoblotting. The level of cofilin phosphorylation 
in the presence of LIMK1 alone was used as the baseline and 
designated 1.0. (B) In vitro kinase assays of coimmunoprecipitated 
FLAG- or GFP-tagged LIMK1 (F- or GFP-LIMK1) or GFP-tagged 
kinase domain of LIMK1 (GFP-KIN) with or without M-BMPR-II. T
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F-actin (Fig. 5 C). However, after incubation with BMP4
for 10–30 min, changes to cell morphology and to the local-
ization of LIMK1 and F-actin were observed. The cells flat-
tened out and formed ruffles at their periphery, and in these
regions, higher levels of LIMK1 and F-actin colocalization
were now evident (Fig. 5 C).
 
LIMK1 expression in pulmonary artery of PPH patient
 
To further understand the effect of BMPR-II mutations on
the possible LIMK1 involvement in the etiology of PPH, we
performed immunohistochemical analysis of a tissue sample
derived from a lung of an individual with PPH using an
anti-LIMK1 antibody. This analysis revealed a high level of
LIMK1 expression in the hyperproliferated smooth muscle
cells of a precapillary pulmonary artery in comparison with
an artery from a normal lung (Fig. 5 D).
 
Discussion
 
The primary function of LIMK1 identified so far is to regu-
late actin dynamics by phosphorylating cofilin (Arber et al.,
1998; Yang et al., 1998). We have shown that BMPR-II as-
sociates with LIMK proteins and subsequently reduces
LIMK1’s ability to phosphorylate cofilin, suggesting that
BMPR-II molecules negatively regulate the activity of
LIMK1. How BMPR-II inhibits the activity of LIMK1 is
not yet clear. It is possible that the binding of LIMK1 via its
LIM domains to the tail of BMPR-II reduces its availability
in the cytoplasm and limits its access to its activators PAK
and ROCK, as we have demonstrated here for PAK4. Signif-
icantly, this inhibitory effect appears to be alleviated by
BMP4 stimulation. It is possible that upon engagement of
the BMP4 ligand by BMPR-II, followed by formation of
BMP–BMPR-II–BMPR-IA complex, LIMK1 is dissociated
from the BMPR-II tail, enabling it to more freely interact
with other proteins, such as its activators, resulting in cofilin
phosphorylation (Fig. 6).
After BMP4 stimulation of COS-7 cells, we observed a
clear change in the subcellular localization of both LIMK1
and F-actin with an apparent increase in polymerized actin
colocalized with LIMK1 at the cell periphery. BMPs are able
to regulate a wide variety of morphogenetic processes during
embryogenesis and in the adult (Hogan, 1996). BMP gradi-
ent concentrations are responsible for migration of cells dur-
ing development. It is possible that the release of LIMK1
from the tail of BMPR-II alters the actin dynamics underly-
ing cell motility. Moreover, it has been shown that BMP4 is
involved in the activation of RhoB during neural crest devel-
Figure 5. Effects of BMP4 on LIMK1 activity and subcellular localization. (A) Immunoblot of COS cell lysates before and after stimulation 
with 10 ng/ml BMP4. The membrane was probed with anti–phospho-cofilin, stripped, and reprobed with anti-cofilin antibodies. The numbers 
below indicate the fold induction of phospho-cofilin level after BMP4 stimulation and were adjusted for the level of cofilin in the lysates. 
(B) Immunoblots of cell lysates prepared from COS cells overexpressing GST–LIMK1, BMPR-II, and both GST–LIMK1 and BMPR-II after or before 
BMP4 stimulation. The filters were probed with anti–BMPR-II (tail), anti-LIMK1 (rat monoclonal), anti–phospho-cofilin, and anti-cofilin 
antibodies. The numbers below indicate the fold induction of phospho-cofilin (P-cofilin) level after BMP4 stimulation and were adjusted 
for the level of cofilin in the lysates. The levels of overexpressed GST–LIMK1 and BMPR-II were consistently much higher when expressed 
separately than when coexpressed in the same cells. (C) Immunofluorescence analysis of endogenous LIMK1 and actin colocalization in 
unstimulated COS-7 cells (top) and in COS-7 cells stimulated with 100 ng/ml BMP4 for 10 min (middle and bottom). Arrowheads highlight 
the coredistribution of LIMK1 and F-actin to the cell’s peripheral ruffles. Bar, 20  M. (D) Immunohistochemical analysis of endogenous 
LIMK1 expression in the precapillary pulmonary artery of normal human lung (i) and in lung tissue from an individual with PPH (ii).T
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opment (Liu and Jessell, 1998), raising the possibility that
BMP4 stimulation additionally activates LIMK1 by phos-
phorylation via the Rho/ROCK pathway.
The redistribution of actin filaments to the periphery of
BMP-stimulated COS-7 cells is similar to that observed in
adenocarcinoma cells stimulated by EGF (Chan et al.,
2000). However, in the case of the EGF-stimulated cells, it
was demonstrated that active cofilin is responsible for the
newly formed actin filaments (Zebda et al., 2000), whereas
in the present study, we observed increased levels of phos-
phorylated cofilin after BMP stimulation. Moreover, Zebda
et al. (2000) have demonstrated that overexpression of the
highly active kinase domain of LIMK1 completely inhibits
the effects of EGF on actin polymerization. However, it is
acknowledged that actin polymerization in vivo depends not
only on severing of actin filaments by cofilin but also via
other mechanisms, the combination of which appears cell
type specific (for review see Condeelis, 2001). Thus, differ-
ent combinations of factors may give rise to the similar actin
polymerization phenotypes observed in BMP-stimulated
COS-7 cells and EGF-stimulated adenocarcinoma cells.
BMPs bind to and activate BMPR-II, which in turn phos-
phorylates and activates BMPR-I, leading to the recruit-
ment, phosphorylation, and subsequent nuclear transloca-
tion of a subset of Smad transcriptional regulators (Shi and
Massague, 2003). Mutations affecting TGF
 
 
 
 signaling path-
ways in most other human disorders target Smad signaling
(Massague et al., 2000). However, this is not the case in
PPH because many of the 
 
BMPRII
 
 mutations target the tail
domain of this receptor, which is dispensable for signaling
via the Smad pathway (Eng, 2001; Nishihara et al., 2002). A
prediction from our study is that these mutations would un-
couple the activation of the Smad signaling pathway from
the regulation of LIMK1 and actin dynamics. An important
question that remains to be addressed is whether the BMPR-
II kinase activity, which is also targeted by certain PPH mu-
tations (Lane et al., 2000; Thomson et al., 2000; Machado
et al., 2001), plays a role in LIMK1 inhibition.
Our preliminary analysis revealed that the level of LIMK1
protein in a precapillary pulmonary artery of an individual
with PPH is increased in the hyperproliferated smooth mus-
cle cells in comparison with normal lung tissue. The in-
creased level of LIMK1 in PPH pulmonary arteries could
also correspond to increases in its activity. We propose that
in PPH patients expressing tailless BMPR-II, LIMK1 activ-
ity is increased because it cannot be controlled by BMPR-II.
Recent experiments in our laboratory suggest that the half-
life of phosphorylated LIMK1 is much longer than that of
the nonphosphorylated protein, and therefore we suspect
that in PPH patients, the higher LIMK1 activity might
translate directly into elevated protein levels. However, it re-
mains to be determined if this dysregulation of LIMK activ-
ity could lead to the hyperproliferation of endothelial and
smooth muscle cells characteristic of PPH.
In summary, the present findings provide a signaling
function for the COOH-terminal tail domain of BMPR-II.
This function is separate from Smad signaling via the associ-
ated type I receptors (Fig. 6). The transcriptional effects of
BMPs and other TGF
 
 
 
 family members via the Smad path-
way have been the subjects of extensive analysis, and their
mechanistic basis is well understood (Hogan, 1996; Shi and
Massague, 2003). However, much less is known about the
molecular basis for the effects of BMP on cell morphology
and migration. Our present results open the door for future
investigation of the link between the BMPR system and the
cytoskeleton via LIMK1.
 
Materials and methods
 
Yeast two-hybrid screens
 
LIMK1, Jun, and Lck bait cDNAs were subcloned into the yeast vector
pGBT9. LIMK1 bait was used in yeast two-hybrid screens of mouse embry-
onic day 11 or human brain MATCHMAKER cDNA libraries (CLONTECH
Laboratories, Inc.) according to the manufacturer’s instructions.
 
Constructs
 
cDNA clones isolated from LIMK1-interacting colonies were subcloned
into the BamHI/XbaI restriction sites of the GFP expression vector pEGFP-
C1 (CLONTECH Laboratories, Inc.). Untagged BMPR-II and HA–PAK4
were obtained from J. Rosenbaum (Procter & Gamble Pharmaceuticals,
Mason, OH) and A. Minden (Columbia University, New York, NY), re-
spectively. LIMK1 and BMPR-II full-length and truncated cDNAs were
cloned into a modified, mammalian expression vector, pEF-BOS, encoding
Figure 6. Schematic representation of two 
signaling outputs from the BMPR system. In the 
canonical Smad signaling process, BMP4 binds to 
and brings together BMPR-I (-IA or -IB, also known 
as ALK3 and ALK6, respectively) and BMPR-II. 
BMPR-II phosphorylates the regulatory region 
(green box) of BMPR-I, activating the kinase domain 
(blue box), which phosphorylates Smad1, leading 
to its nuclear translocation for regulation of target 
genes. The present results show that the COOH-
terminal tail domain (yellow box) of BMPR-II in the 
basal state binds to the LIM domain region of 
LIMK1 and inhibits LIMK1. BMP4 binding relieves 
this inhibitory interaction, enabling LIMK1 to 
phosphorylate cofilin, thereby regulating the 
actin cytoskeleton.T
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either COOH- or NH
 
2
 
-terminal FLAG or myc epitope tags, respectively,
and lacking the puromycin resistance gene and pGK promoter sequences
(Huang et al., 1997).
 
Generation and purification of anti–BMPR-II antibodies
 
A fragment of the human BMP type II receptor comprising amino acids
173–500, including the juxtamembrane and kinase domains, was pro-
duced as a recombinant His
 
6
 
-tagged polypeptide in 
 
Escherichia
 
 
 
coli
 
 using
pRSETA vector and purified using Talon metal affinity resin (CLONTECH
Laboratories, Inc.) according to the manufacturer’s protocol. A fragment
consisting of amino acids 500–899, comprising the COOH-terminal exten-
sion of human BMPR-II, was expressed as a GST fusion protein in 
 
E. coli
 
using pGEX4T1 vector. This fragment was purified as soluble protein using
glutathione-Sepharose beads (Amersham Biosciences) according to the
manufacturer’s protocol and incubated with thrombin (final concentration
10 U/ml) overnight at 4
 
 
 
C to release the polypeptide from the GST tag. The
cleaved polypeptide was resolved by SDS-polyacrylamide gels and cut out
of the gel. These proteins were coupled to CNBr-activated Sepharose (Am-
ersham Biosciences) and used to raise antibodies in rabbits. Antisera were
affinity purified using columns packed with these immunogen-conjugated
Sepharose following standard protocols (Harlow and Lane, 1999).
 
Transfection, immunoprecipitation, and immunoblotting analysis
 
COS-7 cells were electroporated with cDNA constructs using a standard
procedure and grown in DME/10% FCS for 48 h before lysing in a PBS
buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton
X-100, and a cocktail of protease inhibitors (Roche). Lysates were combined
for coimmunoprecipitation analyses essentially as previously described
(Bernard et al., 1994) but using the lysis buffer for the wash buffer. Immu-
noprecipitated proteins or whole lysates were separated on SDS-polyacryl-
amide minigels (Invitrogen) followed by transferring to Hybond-C nitrocel-
lulose filters (Amersham Biosciences). Filters were probed with the
following antibodies at the following dilutions: rabbit anti–BMPR-II jux-
tamembrane polyclonal antibodies, 1:1,000 (provided by J. Rosenbaum);
rabbit anti–phospho-cofilin polyclonal antibodies, 1:1,000 (provided by J.
Bamburg, Colorado State University, Fort Collins, CO); rabbit anti-cofilin
polyclonal antibodies, 1:5,000 (provided by J. Bamburg); rabbit anti-GST
polyclonal antibodies, 1:4,000 (AMRAD); rabbit anti-GFP polyclonal anti-
bodies, 1:3,000 (Molecular Probes); mouse anti–FLAG M2 monoclonal an-
tibody, 1:10,000 (Sigma-Aldrich); and mouse anti-myc antibody mono-
clonal, 1:6,000 (Zymed Laboratories). Bound primary antibodies were
visualized with the horseradish peroxidase–conjugated secondary antibod-
ies, goat anti–mouse, goat anti–rat, or goat anti–rabbit IgG (Silenus). To de-
tect the interaction between endogenous BMPR-II and LIMK1, NIH3T3
cells were lysed in buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl,
10 mM NaF, 10 mM 
 
 
 
-glycerolphosphate, 10% glycerol, 0.5% NP-40, 1
mM DTT, and a cocktail of protease inhibitors (Roche). Immunoprecipita-
tions were performed as previously described (Chen et al., 2002). The fol-
lowing antibody dilutions were used: 1:500 for mouse anti-LIMK1 (BD
Biosciences) and 1:1,000 for rabbit anti–BMPR-II (tail and kinase).
 
GST and FLAG affinity purification
 
Cell lysates containing overexpressed GST- or FLAG-tagged proteins were
incubated with glutathione-Sepharose beads (Amersham Biosciences) or
with anti–FLAG M2 beads (Sigma-Aldrich), respectively. Bound FLAG-
tagged proteins were eluted with 100 
 
 
 
g/ml FLAG peptide (Sigma-
Aldrich), and GST-tagged proteins were released after boiling for 5 min.
 
In vitro kinase assays
 
Electroporated COS-7 cells were lysed in PBS containing 20 mM Hepes
(pH 7.4), 150 mM KCl, 0.1% Triton X-100, protease inhibitors, 10 mM
NaF, 1 mM Na
 
3
 
VO
 
4
 
, and 10 mM NaP
 
2
 
O
 
7
 
 and sonicated for 10 s. Immu-
nopurified proteins were subjected to an in vitro kinase assay and recov-
ered using ProbeQuant G-50 microcolumns (Amersham Biosciences).
These columns increase reproducibility and protein recovery of immuno-
precipitated protein complexed (Brymora et al., 2001). In brief, the
ProbeQuant G-50 beads were removed, and the protein–antibody-coupled
Sepharose beads were pipetted into the column. Under vacuum aspiration,
the samples were washed three times in 1 ml of the Hepes lysis buffer and
twice with the in vitro kinase assay buffer (20 mM Hepes, pH 7.4, 150 mM
MgCl
 
2
 
, 10 mM MnCl
 
2
 
, 10 mM NaF, and 1 mM Na
 
3
 
VO
 
4
 
 in PBS). The in
vitro kinase assay was performed as previously described (Arber et al.,
1998). To elute the phosphorylated bound protein complexes, the columns
were capped, boiled for 5 min in 1.5-ml microtubes, and the protein–anti-
body complexes were collected from the columns by centrifugation. After
electrophoresis and Western blotting, phosphorylated proteins were de-
tected and quantitated using a PhosphorImager (400 series; Molecular Dy-
namics). The loading of proteins was determined after immunoblotting and
densitometry analysis.
 
Expression of endogenous LIMK1 in COS-7 cells and tissue sections
 
COS-7 cells (5 
 
 
 
 10
 
3
 
) were plated on fibronectin-treated coverslips in a
24-well plate and incubated with DME containing 10% FCS for 24 h. The
cells were washed with PBS and incubated for 4 h with DME before addi-
tion of BMP4 (R&D Systems) (100 ng/ml) for 1, 5, 10, 30, and 60 min. The
cells were fixed with 1% paraformaldehyde, washed with PBS, and perme-
abilized for 1 h with PBS containing 2% normal goat serum, 5% FCS, and
0.1% Tween-20. Endogenous LIMK1 expression was detected using a rat
anti-LIMK1 monoclonal antibody (Yoshioka et al., 2003) at a 1:500 dilu-
tion followed by Alexa
 
®
 
488 anti–rat IgG (1:7,500; Molecular Probes).
F-actin was stained with TRITC–phalloidin (Molecular Probes). The cover-
slips were mounted using antifade mounting medium (DakoCytomation)
and visualized by confocal microscopy. Paraffin-embedded tissue sections
were treated and stained as previously described (O’Reilly et al., 1998)
with the rat anti-LIMK1 monoclonal antibody (1:100 dilution).
 
BMP4 stimulation of COS cells
 
COS cells (10
 
4
 
) were plated onto 6-cm dishes, and 24 h later, they were
washed three times with PBS and serum starved for 4 h in DME before ad-
dition of 10 ng/ml BMP4 (R&D Systems) diluted in 0.1% BSA in PBS for
5–30 min. Control plates were incubated for the same time periods in
0.1% BSA in PBS. Cells were lysed in lysis buffer and were subjected to
Western blot analysis as described above.
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